MaxCyte's Operating Income for the
three
months ended in Mar. 2026 was $-6.19 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.18 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. MaxCyte's Operating Income for the
three
months ended in Mar. 2026 was $-6.19 Mil. MaxCyte's Revenue for the
three
months ended in Mar. 2026 was $9.65 Mil. Therefore, MaxCyte's Operating Margin % for the quarter that ended in Mar. 2026 was -64.09%.
Warning Sign:
MaxCyte Inc operating margin has been in a 5-year decline. The average rate of decline per year is -30.2%.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
MaxCyte's annualizedROC % for the quarter that ended in Mar. 2026 was -28.72%.
MaxCyte's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -75.49%.
MaxCyte (NAS:MXCT) Operating Income Explanation
1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
MaxCyte's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
MaxCyte Operating Income Related Terms
MaxCyte Operating Income Historical Data
* Premium members only.
The historical data trend for MaxCyte's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Operating Income of $-39.18 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on MaxCyte and its competitors.
Is MaxCyte's Operating Income too high?
MaxCyte's current Operating Income is $-39.18 Mil. Overall, MaxCyte has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Operating Income compare to RCEL and HYPR?
MaxCyte's Operating Income of $-39.18 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on MaxCyte and its competitors. MaxCyte's current Operating Income is $-39.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.30 — trading 49.4% below its estimated fair value. The current Operating Income is $-39.18 Mil. MaxCyte's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For MaxCyte (MXCT), the current Operating Income is $-39.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.30 is trading 49.4% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Operating Income: $-39.18 Mil
GF Value™: $2.57 vs. price of $1.30 (49.4% below fair value)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
59GF Score
Get the complete analysis for MXCT
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
